Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
D.A. Drossman.
A biopsychosocial understanding of gastrointestinal illness and disease.
Sleisenger and Fordtran's gastrointestinal and liver disease 7th e.d, pp. 2373-2385
[2.]
M. Camilleri.
Testing the sensitivity hypothesis in practice: tools and methods, assumptions and pitfalls.
Gut, 51 (2002), pp. 34-40
[3.]
D.A. Drossman.
Chronic abdominal pain (with enphasis in functional pain syndrome).
Sleisenger and Fordtran's gastrointestinal and liver disease 7th e.d, pp. 84-92
[4.]
J. Ritchie.
Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome.
Gut, 14 (1973), pp. 125-132
[5.]
W.E. Whitehead, B. Holtkotter, P. Enck, R. Hoelzl, K.D. Holmes, J. Anthony, et al.
Tolerance for rectosigmoid distension in irritable bowel syndrome.
Gastroenterology, 98 (1990), pp. 1187-1192
[6.]
M. Bradette, M. Delvaux, G. Staumont, J. Fioramonti, L. Bueno, J. Frexinos.
Evaluation of colonic sensory thresholds in IBS patients using a barostat. Definition of optimal conditions and comparison with healthy subjects.
Dig Dis Sci, 39 (1994), pp. 449-457
[7.]
K.C. Trimble, R. Farouk, A. Pryde, S. Douglas, R.C. Heading.
Heightened visceral sensation in functional gastrointestinal disease is not site-specific. Evidence for a generalized disorder of gut sensitivity.
Dig Dis Sci, 40 (1995), pp. 1607-1613
[8.]
F. Mearin, M. Cucala, F. Azpiroz, J-R. Malagelada.
The origin of symptoms on the brain-gut axis in functional dyspepsia.
Gastroenterology, 101 (1991), pp. 999-1006
[9.]
I.J. Cook, A. Van Eeden, S.M. Collins.
Patients with irritable bowel syndrome have a greater pain tolerance than normal subjects.
Gastroenterology, 93 (1987), pp. 727-733
[10.]
A.M. Accarino, F. Azpiroz, J.R. Malagelada.
Selective dysfunction of mechanosensitive intestinal afferents in irritable bowel syndrome.
Gastroenterology, 108 (1995), pp. 636-643
[11.]
H. Mertz.
Role of brain and sensory pathways in gastrointestinal sensory disorders in humans.
Gut, 51 (2002), pp. 29-33
[12.]
N.W. Read.
Rectal distention: from sensation to feeling.
Gastroenterology, 118 (2000), pp. 972-973
[13.]
W.E. Whitehead, M. Delvaux.
Standardization of barostat procedures for testing smooth muscletone and sensory thresholds in the gastrointestinal tract. The working team of Glaxo-Wellcome, UK.
Dig Dis Sci, 42 (1997), pp. 223-241
[14.]
E. Rey, A. Álvarez Sánchez, M. Díaz-Rubio.
¿Cuál es el mejor protocolo de distensión para estudiar la sensibilidad rectal en el síndrome de intestino irritable?.
Rev Esp Enferm Dig, 94 (2002), pp. 211-215
[15.]
E. Distrutti, F. Azpiroz, A. Soldevilla, J.R. Malagelada.
Gastric wall tension determines perception of gastric distention.
Gastroenterology, 116 (1999), pp. 1035-1042
[16.]
H. Gregersen.
Development of a tensostat for gastric perception studies.
Gastroenterology, 118 (2000), pp. 641-643
[17.]
W.E. Whitehead, O.S. Palsson.
Is rectal pain sensitivity a biological marker for irritable bowell syndrome: psychological influences on pain perception.
Gastroenterology, 115 (1998), pp. 1263-1271
[18.]
B. Dickhaus, E.A. Mayer, N. Firooz, J. Stains, F. Conde, T.I. Olivas, et al.
Irritable bowel syndrome patients show entranced modulation of visceral perception by auditory stress.
Am J Gastroenterology, 98 (2003), pp. 135-143
[19.]
A.M. Accarino, F. Azpiroz, J.R. Malagelada.
Attention and distraction: effects on gut perception.
Gastroenterology, 113 (1997), pp. 415-422
[20.]
B.D. Naliboff, J. Munakata, S. Fullerton, R.H. Gracely.
Evidence for two distinct perceptual alterations in irritable bowel syndrome.
Gut, 41 (1997), pp. 505
[21.]
H. Mertz, V. Morgan, G. Tanner, D. Pickens, R. Price, Y. Shyr, et al.
Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention.
Gastroenterol, 118 (2000), pp. 842-848
[22.]
B. Bonaz, M. Baciu, E. Papillon, R. Bost, N. Gueddah, J.F. Le Bas, et al.
Central processing of rectal pain in patients with irritable bowel syndrome: an fMRI study.
Am J Gastroenterol, 97 (2002), pp. 654-661
[23.]
C.N. Berstein, U.N. Frankenstein, P. Rawsthorne, et al.
Cortical mapping of viscerla pain in patients with gastrointestinal disorders using functional magnetic resonance imaging.
Am J Gastroenterol, 97 (2002), pp. 319-327
[24.]
B.D. Naliboff, S. Berman, L. Chang, S.W.G. Derbyshire, B. Suyenobu, B.A. Vogt, et al.
Sex-related differences in IBS patients: central processing of visceral stimuli.
Gastroenterology, 124 (2003), pp. 1738-1747
[25.]
A. Prior, E. Sorial, W.M. Sun, N.W. Read.
Irritable bowel syndrome: differences between patientes who show rectal sensitivity and those who do not.
Eur J Gastroenterol Hepatol, 5 (1993), pp. 343-349
[26.]
H. Mertz, B. Naliboff, J. Munakata, N. Niazi, E.A. Mayer.
Altered rectal perception is a biological marker of patients with irritable bowel syndrome.
Gastroenterology, 109 (1995), pp. 40-52
[27.]
M. Bouin, V. Plourde, M. Boivin, M. Riberdy, F. Lupien, M. Laganiere, et al.
Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds.
Gastroenterology, 122 (2002), pp. 1771-1777
[28.]
M. Bradette, P. Pare, P. Douville, A. Morin.
Visceral perception in health and functional dyspepsia. Crossover study of gastric distension with placebo and domperidone.
Dig Dis Sci, 36 (1991), pp. 52-58
[29.]
M. Lemann, J.P. Dederding, B. Flourie, C. Franchisseur, J.C. Rambaud, R. Jian.
Abnormal perception of visceral pain in response to gastric distension in chronic idiopathic dyspepsia. The irritable stomach syndrome.
Dig Dis Sci, 36 (1991), pp. 1249-1254
[30.]
H. Mertz, S. Fullerton, B. Naliboff, E.A. Mayer.
Symptoms and visceral perception in severe functional and organic dyspepsia.
Gut, 42 (1998), pp. 814-822
[31.]
A. Castro, F. Mearin, I. Romero, M. Torné, M.J. Varas, J-R. Malagelada.
Symptomatic hypersensitivity to intragastric lipid infusion and i.v.
CCK in functional dyspepsia: role of gastric accommodation and gallbladder emptying Gastroenterology, 112 (1997), pp. A709
[32.]
R. Barbera, C. Feinle, N.W. Read.
Abnormal sensitivity to duodenal lipid infusion in patients with functional dyspepsia.
Eur J Gastroenterol Hepatol, 11 (1995), pp. 1051-1057
[33.]
R. Barbera, C. Feinle, N.W. Read.
Nutrient-specific modulation of gastric mechanosensitivity in patients with functional dyspepsia.
Dig Dis Sci, 8 (1995), pp. 1636-1641
[34.]
J. Tack Tack, P. Caenepeel, B. Fischler, H. Piessevaux, J. Janssens.
Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia.
Gastroenterology, 121 (2001), pp. 526-535
[35.]
L. Marzio, M. Falcucci, L. Grossi, F.A. Ciccaglione, M.G. Malatesta, A. Castellano, et al.
Proximal and distal gastric distension in normal subjects and H. pylori-positive and -negative dyspeptic patients and correlation with symptoms.
Dig Dis Sci, 43 (1998), pp. 2757-2763
[36.]
G.E. Boeckxstaens, D.P. Hirsch, S.D. Kuiken, S.H. Heisterkamp, G.N. Tytgat.
The proximal stomach and postprandial symptoms in functional dyspeptics.
Am J Gastroenterol, 97 (2002), pp. 40-48
[37.]
L.M. Bernstein, L.A. Baker.
A clinical test for esophagitis.
Gastroenterology, 34 (1958), pp. 760-781
[38.]
K.C. Trimble, A. Pryde, R.C. Heading.
Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GERD.
Gut, 37 (1995), pp. 7-12
[39.]
G. Holtmann.
(Post) inflammatory visceral hyperalgesia: don't we believe what we don't see?.
Gastroenterology, 122 (2002), pp. 823-825
[40.]
J. Munakata, B. Naliboff, F. Harraf, A. Kodner.
Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome.
Gastroenterology, 112 (1997), pp. 55-63
[41.]
A. Aggarwal, T.F. Cutts, T.L. Abell, S. Cardoso, B. Familoni, J. Bremer, et al.
Predominant symptoms in irritable bowel syndrome correlatewith specific autonomic nervous system abnormalities.
Gastroenterology, 106 (1994), pp. 945-950
[42.]
R.E. Clouse.
Managing functional bowel disorders from the top down: lessons from a well-designed treatment trial.
Gastroenterology, 125 (2003), pp. 249-259
[43.]
L.J. Brandt, D. Bjorkman, M.B. Fennerty, G.R. Locke, K. Olden, W. Peterson, et al.
Systematic review on the management of irritable bowel syndrome in North America.
Am J Gastroenterol, 97 (2002), pp. 7-26
[44.]
J.L. Jackson, P.G. O'Malley, G. Tomkins, E. Balden, J. Santoro, K. Kroenke.
Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis.
Am J Med, 108 (2000), pp. 65-72
[45.]
D.A. Drossman, B.B. Toner, W.E. Whitehead, N.E. Diamant, C.B. Dalton, S. Duncan, et al.
Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders.
Gastroenterology, 125 (2003), pp. 19-31
[46.]
A.B. Gorelick, S.S. Koshy, F.G. Hooper, T.C. Bennett, W.D. Chey, W.L. Hasler.
Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans.
Am J Physiol, 275 (1998), pp. G460-G466
[47.]
H. Mertz, R. Fass, A. Kodner, F. Van-Go, S. Fullerton, E.A. Mayer.
Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia.
Am J Gastroenterol, 93 (1998), pp. 160-165
[48.]
A. Langlois, L. Diop, N. Friese, X. Pascaud, J.L. Junien, S.G. Dahl, et al.
Fedotozine blocks hypersensitive visceral pain in conscious rats: actino at peripheral kappa-opiod receptors.
Eur J Pharmacol, 324 (1997), pp. 211-217
[49.]
B. Coffin, D. Bouhassira, R. Chollet, B. Fraitag, C. De Meynard, J. Geneve, et al.
Effect of the kappa agonist fedotozine on perception of gastric distension in healthy humans.
Aliment Pharmacol Ther, 10 (1996), pp. 919-925
[50.]
M. Delvaux, D. Louvel, E. Lagier, B. Scherrer, J.L. Abitbol, J. Frexinos.
The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome Gastroenterology, 116 (1999), pp. 38-45
[51.]
B. Fraitag, M. Homerin, P. Hecketsweiler.
Double-blind doseresponse multicenter comparison of fedotozine and placebo in treatment of nonulcer dyspepsia.
Dig Dis Sci, 39 (1994), pp. 1072-1077
[52.]
N.W. Read, J.L. Abitbol, K.D. Bardhan, P.J. Whorwell, B. Fraitag.
Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia.
Gut, 41 (1997), pp. 664-668
[53.]
M. Dapoigny, J.L. Abitbol, B. Fraitag.
Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study.
Dig Dis Sci, 40 (1995), pp. 2244-2249
[54.]
S. Delgado-Aros, H.J. Chial, M. Camilleri, L.A. Szarka, F.T. Weber, J. Jacob, et al.
Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans.
Am J Physiol Gastrointest Liver Physiol, 284 (2003), pp. G558-G566
[55.]
M. Delvaux, J. Jacob, A. Beck, H. Bouzamondo, F. Weber, J. Frexinos.
Effect of asimadoline, a new agonist of peripheral kappa opiate receptor son pain induced by rectal distension in IBS patients.
Gastroenterology, 14 (2003), pp. A-221
[56.]
W.L. Hasler, H.C. Soudah, C. Owyang.
A somatostatin analogue inhibits afferent pathways mediating perception of rectal distention.
Gastroenterology, 104 (1993), pp. 1390-1397
[57.]
V. Plourde, T. Lembo, Z. Shui, J. Parker, H. Mertz, Y. Tache, et al.
Effects of the somatostatin analogue octreotide on rectal afferent nerves in humans.
Am J Physiol, 265 (1993), pp. G742-G751
[58.]
W.D. Chey, A. Beydoun, D.J. Roberts, W.L. Hasler, C. Owyang.
Octreotide reduces perception of rectal electrical stimulation by spinal afferent pathway inhibition.
Am J Physiol, 269 (1995), pp. G821-G826
[59.]
H. Mertz, J.H. Walsh, B. Sytnik, E.A. Mayer.
The effect of octreotide on human gastric compliance and sensory perception.
Neurogastroenterol Motil, 7 (1995), pp. 175-185
[60.]
A. Foxx-Orestein, M. Camilleri, D. Stephens, D. Burton.
Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans.
Gut, 52 (2003), pp. 1555-1561
[61.]
W.L. Hasler, H.C. Soudah, C. Owyang.
Somatostatin analog inhibits afferent response to rectal distention in diarrhea-predominant irritable bowel patients.
J Pharmacol Exp Ther, 268 (1994), pp. 1206-1211
[62.]
Farthing MJG.
New drugs in the management of the irritable bowel syndrome.
Drugs, 56 (1998), pp. 11-21
[63.]
L.A. Houghton, J.M. Foster, P.J. Whorwell.
Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers.
Aliment Pharmacol Ther, 14 (2000), pp. 775-782
[64.]
M.J.R. Stark, K. Maher, P. Gupta.
Visceral afferent blockade with ondansetron increases nociceptive thresholds in patients with non-cardiac chest pain.
Am J Gastroenterol, 18 (1991), pp. A129
[65.]
M. Delvaux, D. Louvel, J.P. Mamet, R. Campos-Oriola, J. Frexinos.
Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.
Aliment Pharmacol Ther, 12 (1998), pp. 849-855
[66.]
P.A. Goldberg, M.A. Kamm, P. Setti-Carraro, J.R. Van der Sijp, C. Roth.
Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron).
Digestion, 57 (1996), pp. 478-483
[67.]
M. Thumshirn, B. Coulie, M. Camilleri, A.R. Zinsmeister, D.D. Burton, C. Van Dyke.
Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome.
Aliment Pharmacol Ther, 14 (2000), pp. 869-878
[68.]
F. Zerbib, S. Bruley des Varannes, R.C. Oriola, J. McDonald, J.P. Isal, J.P. Galmiche.
Alosetron does not affect the visceral perception of gastric distension in healthy subjects.
Aliment Pharmacol Ther, 8 (1994), pp. 403-407
[69.]
J. Tack, A. Wilmer, B. Couli.
Influence of ondansetron on gastric tone and on the percepcion of gastric distention.
Gut, 46 (2000), pp. 468-473
[70.]
R.H. Jones, G. Holtmann, L. Rodrigo, R.S. Ehsanullah, P.M. Crompton, L.A. Jacques, et al.
Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients.
Aliment Pharmacol Ther, 13 (1999), pp. 1419-1427
[71.]
M. Camilleri, E.A. Mayer, D.A. Drossman, A. Heath, G.E. Dukes, D. McSorley, et al.
Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist.
Aliment Pharmacol Ther, 13 (1999), pp. 1149-1159
[72.]
T. Lembo, R.A. Wright, B. Bagby, C. Decker, S. Gordon, P. Jhingran, et al.
Lotronex Investigator Team. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.
Am J Gastroenterol, 96 (2001), pp. 2662-2670
[73.]
E.A. Mayer, S. Berman, S.W. Derbyshire, B. Suyenobu, L. Chang, L. Fitzgerald, et al.
The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients.
Aliment Pharmacol Ther, 16 (2002), pp. 1357-1366
[74.]
N.J. Talley, S.V. Van Zanten, L.R. Sáez, G. Dukes, T. Perschy, M. Heath, et al.
A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia.
Aliment Pharmacol Ther, 15 (2001), pp. 525-537
[75.]
C.M. Prather, M. Camilleri, A.R. Zinsmeister, C.M. Prather, M. Camilleri, A.R. Zinsmeister, et al.
Tegaserod accelerates transit in patients with constipation-predominant irritable bowel síndrome.
Gastroenterology, 118 (2000), pp. 463-468
[76.]
A. Schikowski, C. Mathis, M. Thewissen, et al.
Dose dependent modulation of rectal afferent sensitivity by a 5-HT4 receptor agonist.
Gastroenterology, 17 (1999), pp. A643
[77.]
B. Coffin, J.P. Farmachidi, P. Rueegg, A. Bastie, D. Bouhassira.
Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects.
Aliment Pharmacol Ther, 17 (2003), pp. 577-585
[78.]
J. Tack, R. Vos, J. Janssens, J. Salter, S. Jauffret, G. Vandeplassche.
Influence of tegaserod on proximal gastric tone and on the perception of gastric distension.
Aliment Pharmacol Ther, 18 (2003), pp. 1031-1038
[79.]
S.A. Müller-Lissner, I. Fumagalli, K.D. Bardhan, F. Pace, E. Pecher, B. Nault, et al.
Tegaserod, a 5-HT4 receptor agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation.
Aliment Pharmacol Ther, 15 (2001), pp. 1655-1656
[80.]
C. Feinle, T. Rades, B. Otto, M. Fried.
Fat digestion modulates gastrointestinal sensations induced by gastric distention and duodenal lipid in humans.
Gastroenterology, 120 (2001), pp. 1100-1107
[81.]
L. Barrow, P.E. Blackshaw, G. Clive, et al.
Selective slowing of proximal colon transit in irritable bowel syndrome by the cholecystokinin-receptor antagonist, loxiglumide.
Eur J Gastroenterol Hepatol, 6 (1994), pp. 381-387
[82.]
C. Feinle, O. Meier, B. Otto, M. D'Amato, M. Fried.
Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia.
Gut, 48 (2001), pp. 347-355
[83.]
A. Chua, M. Bekkering, L.C. Rovati, P.W.N. Keeling.
Clinical efficacy and prokinetic effect of the CCK-A antagonist loxiglumide in nonulcer dyspepsia.
Gastroenterology, 104 (1993), pp. A491
[84.]
A.E. Bharucha, M. Camilleri, A.R. Zinsmeister, R.B. Hanson.
Adrenergic modulation of human colonic motor and sensory function.
Am J Physiol, 273 (1997), pp. 997-1006
[85.]
M. Thumshirn, M. Camilleri, M.G. Choi, A.R. Zinsmeister.
Modulation of gastric sensory and motor functions by nitrergic and alpha2-adrenergic agents in humans.
Gastroenterology, 116 (1999), pp. 573-585
[86.]
S. Bradesi, H. Eutamene, R. García-Villar, J. Fioramonti, L. Bueno.
Stress-induced visceral hypersensitivity in female rats is estrogen-dependent and involves tachykinin NK1 receptors.
Pain, 102 (2003), pp. 227-234
[87.]
A.M. Coelho, N. Vergnolle, B. Guiard, J. Fioramonti, L. Bueno.
Proteinases and proteinase-activated receptor 2: a possible role to promote visceral hyperalgesia in rats.
Gastroenterology, 122 (2002), pp. 1035-1047
[88.]
M. Toulouse, A.M. Coelho, J. Fioramonti J Fioramonti, A. Lecci, C. Maggi, et al.
Role of tachykinin NK2 in normal and altered rectal sensitivity in rats.
Br J Pharmacol, 129 (2000), pp. 193-199
[89.]
F. Mearin, A. Balboa, N. Zarate, M. Cucala, J-R. Malagelada.
Placebo in functional dyspepsia: symptomatic, gastrointestinal motor, and gastric sensorial responses.
Am J Gastroenterol, 94 (1999), pp. 116-125
[90.]
L.A. Houghton, E.L. Calvert, N.A. Jackson, P. Cooper, P.J. Whorwell.
Visceral sensation and emotion: a study using hypnosis.
Gut, 51 (2002), pp. 701-704
[91.]
P.J. Whorwell, A. Prior, E.B. Faragher.
Controlled trial of hypnotherapy in the treatment of severe refractory irritable bowell syndrome.
Lancet, 2 (1984), pp. 1232-1234
[92.]
P.J. Whorwell, A. Prior, S.M. Colgan.
Hypnotherapy in severe irritable bowel syndrome: further experience.
Gut, 28 (1987), pp. 423-425
[93.]
E.L. Calvert, L.A. Houghton, P. Cooper, J. Morris, P.J. Whorwell.
Long-term improvement in functional dyspepsia using hypnotherapy.
Gastroenterology, 123 (2002), pp. 1778-1785
Copyright © 2004. Elsevier España, S.L.. Todos los derechos reservados
